The company's multibillion-dollar investments in manufacturing in the U.S. are likely to be warmly welcomed by the Trump administration.
Eli Lilly's management has already committed to taking action to lower pharmaceutical prices in the U.S.
Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical company three years of grace from tariffs imposed on drugs it manufactures abroad and imports to the U.S.. The deal, which is conditional on Pfizer investing in manufacturing in the U.S., raises hopes that Eli Lilly will also come to a similar agreement with the government.
Eli Lilly is in a good position for a couple of reasons. First, it's already investing heavily in the U.S. with a $5 billion manufacturing facility planned in Virginia, as well as a $6.5 billion manufacturing facility planned in Texas.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Second, Eli Lilly has already announced an intent to rebalance the costs of its research by increasing the prices paid by governments and healthcare bodies "in other developed markets like Europe in order to make them lower in the U.S."
With negotiations ongoing and the Trump administration unlikely to impose pharmaceutical tariffs on Eli Lilly and others until they are finalized, the odds look favorable for the company to reach some form of agreement with the administration, just as Pfizer did.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $626,942!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,157,870!*
Now, it’s worth noting Stock Advisor’s total average return is 1,063% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of September 29, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.